~21% Revenue CAGR for 16 Years Through Micro-Cap Scientific Instrument Acquisitions at 4–6x EBIT
Grew revenue ~22x to £136M in 16 years acquiring 25+ niche instrument businesses at 4–6x EBIT.
Judges Scientific, a Mid-Market Serial Acquirers & Roll-ups company, created value through New Customer Acquisition and Market Entry and Team Structure and Accountability.
Judges Scientific was incorporated in 2002 by David Cicurel, a financier who identified a structural anomaly in the UK scientific instruments sector: hundreds of founder-owned businesses making highly specialised measurement, testing, and laboratory equipment — serving niches such as fire testing, materials analysis, and electron microscopy — were generating 20–30%+ returns on tangible capital but trading at 4–7x EBIT whenever they came to market. The anomaly was supply-side. These businesses were too small for industrial conglomerates such as Danaher or Ametek, too niche for generalist private equity, and too capital-light to attract infrastructure buyers. Founders reaching retirement had two realistic options: a trade sale to a larger company that would absorb and homogenise their business, or a management buyout that required their own team to take on debt. Cicurel constructed a third option — sell to Judges Scientific, retain full operational control, keep staff, premises, and brand intact, stay on under an earnout for three to five years, and continue running the business you built.
By FY2007, Judges Scientific had completed its first acquisitions and was generating approximately £6.2 million in annual revenue across two to three subsidiaries. The strategic question was whether the model — acquiring niche businesses at low multiples and leaving them entirely alone operationally — could compound returns durably without requiring integration or exceptional organic growth from each acquired subsidiary.
Cicurel developed explicit acquisition criteria that excluded the majority of the market. Targets had to be UK-based, operating in scientific instruments or test and measurement equipment, generating at least 15–20% pre-tax profit margins, with a defensible market position built on specialist IP or long-standing customer relationships, and — critically — with a management team willing to remain post-acquisition. Businesses in commoditised or high-capital-intensity categories were excluded. The target size range was typically £2M to £30M in annual revenue.
The head office model was deliberately minimalist: Cicurel and fewer than five corporate staff, providing no shared services, no centralised procurement, no group IT infrastructure, and no imposed brand standards. Each subsidiary retained its own banking relationship, its own management reporting cadence, and full autonomy over pricing, hiring, and operational decisions. The group did not seek post-acquisition synergies; each acquisition was evaluated on standalone merit, and financial contribution was expected immediately.
| Metric | FY2007 | FY2023 |
|---|---|---|
| Annual revenue | ~£6.2M | £136.1M (~22x) |
| Revenue CAGR (16 years) | — | ~21% |
| Adjusted EBIT margin | — | ~25.6% |
| ROCE (pre-goodwill) | — | >25% |
| Post-goodwill ROCE | — | ~15–18% |
| Acquisitions completed (cumulative) | 2–3 | ~20 |
| Avg. acquisition multiple | 4–6x EBIT | 4–6x EBIT |
| Head office staff | ~5 | ~5 |
| Share price CAGR (2007–2022) | — | ~22% |
Organic growth contributed approximately 5–8% per annum; acquisitions provided the balance. Halma's ROCE target is 12%+ post-goodwill; Diploma's ROCE is approximately 18–20%.
Judges Scientific's economics reduce to a single insight: if you acquire businesses generating 20–30% ROCE on tangible capital at 4–6x EBIT rather than 8–15x EBIT, you compound returns at rates that integration-hungry buyers cannot match, because they are paying twice the price for the same underlying asset quality.
The multiple gap is not maintained through superior negotiating skill or financial engineering. It is maintained through three structural choices that reinforce each other. First, Cicurel targets sellers who prioritise continuity over maximum consideration — founders who want their business to survive them as they built it, not be absorbed into a larger entity. These sellers accept lower prices in exchange for that guarantee. Second, the non-integration promise has to be credible: Judges Scientific cannot attract continuity-motivated sellers if those sellers suspect the promise will be broken once they sign. The minimalist head office — under five people, no shared services, no group brand — is the structural proof that the promise is kept. It costs almost nothing, and it is the mechanism that makes below-market deal flow possible. Third, the earnout structure keeps founders operating the businesses rather than exiting, which means the acquired business continues to benefit from the same human capital — often embodied knowledge of a niche product and its customers — that generated the ROCE in the first place.
The synthesis point the case study implies but does not state directly: most roll-up strategies destroy value not because acquisition multiples are too high but because integration destroys the ROCE of the underlying asset. Judges Scientific's model is unusual precisely because it separates the financial transaction of acquisition from any operational disruption — and the low acquisition multiples are only achievable because the seller believes (correctly) that the separation will be permanent. The case study does not address the scaling question: whether a head office of five people can maintain governance quality and acquisition discipline at 40 or 60 subsidiaries, or whether growth beyond a certain point requires adding corporate overhead that erodes the cost advantage. That is the open question for Judges Scientific as the portfolio expands.
27%+ EBITDA Margins Through Decentralized Niche Acquisition Strategy
153% Revenue Growth Through Serial Acquisition of Niche Aerospace Parts Businesses
Acquisitions were structured with a significant portion of consideration paid as deferred earnout, typically over three to five years and tied to each subsidiary's own financial performance. This mechanism converted founders who would otherwise retire into motivated operators with a continuing financial stake in the businesses they had sold.
Between 2007 and 2023, Judges Scientific completed approximately 25 acquisitions. A representative transaction was the 1 April 2016 acquisition of Dia-Stron Ltd, a Hampshire-based manufacturer of instruments for testing the mechanical properties of hair and fibres, for total consideration of £2.75 million cash against revenues of approximately £1.48 million — approximately 4.2x EBIT, consistent with the group's stated 4–6x EBIT range. The founding team remained in operational control post-acquisition.
The group's average acquisition multiple across its history has been approximately 4–6x EBIT, materially below the 8–15x EBIT multiples paid by larger listed acquirers such as Halma or Diploma. This multiple gap — driven by Judges Scientific's ability to source deals off-market from founders who prioritised business continuity over maximum consideration — was the primary source of value creation in the model.
From £6.2 million in FY2007, Judges Scientific grew revenue to £113.2 million in FY2022 and £136.1 million in FY2023 — approximately a 22-fold increase over 16 years, representing a compound annual growth rate of approximately 21%. Adjusted EBIT reached approximately £34.8 million in FY2023, implying an adjusted margin of approximately 25.6%.
Return on capital employed on tangible assets (pre-goodwill) consistently exceeded 25% across the period. After incorporating goodwill from the low-multiple acquisitions, post-goodwill ROCE averaged approximately 15–18% — above Halma's stated 12%-plus target on total capital and broadly comparable to Diploma's approximately 18–20% ROCE. Organic revenue growth contributed approximately 5–8 percentage points annually; acquisitions provided the balance of total growth.
The AIM-listed shares compounded at approximately 22% per annum from 2007 to 2022, materially outperforming both the AIM All-Share and FTSE All-Share indices over the same period.
By FY2023, the portfolio comprised approximately 25 subsidiaries, each operating independently under its own management team. The corporate centre remained under five people and represented less than 1% of group revenue in overhead cost.
Three structural conditions sustained the model across 16 years.
The fragmentation and low visibility of the UK scientific instruments sector created a deal pipeline large relative to Judges Scientific's acquisition capacity. With hundreds of founder-owned businesses spread across sub-sectors — fire testing equipment, materials characterisation instruments, laser accessories, neuroscience tools — and no dominant consolidator targeting them, Judges Scientific could access deals off-market through direct founder relationships rather than competitive auction processes. Off-market access was the mechanism through which 4–6x EBIT multiples were achievable: competitive auctions drive multiples up; direct relationships allow price to reflect seller preferences beyond pure maximum consideration.
The deliberate refusal to integrate acquired businesses eliminated the operational costs and cultural disruption that typically erode returns in roll-up strategies. By promising — and maintaining — full operational autonomy, Judges Scientific retained the human capital assets embedded in each subsidiary and avoided the execution risk that scale brings to integration-dependent acquirers. Management turnover post-acquisition was low because no integration event disrupted reporting lines, compensation structures, or operating practices.
The earnout structure converted sellers from exit events into performance partnerships. Founders receiving a meaningful portion of consideration over three to five years as a function of their own business's financial performance were not incentivised to coast post-acquisition. The combination of continued management control and deferred financial upside replicated the owner-operator incentive structure that had made each acquired business profitable before Judges Scientific owned it.
15% EBITA Margin at SEK 22B Revenue Through Niche-Tech Acquisition Roll-up